Exact Sciences (EXAS) Competitors $64.64 -0.21 (-0.32%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$64.55 -0.09 (-0.14%) As of 10/24/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXAS vs. BIIB, UTHR, INCY, NBIX, IONS, EXEL, BMRN, MDGL, RGEN, and HALOShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), Repligen (RGEN), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Its Competitors Biogen United Therapeutics Incyte Neurocrine Biosciences Ionis Pharmaceuticals Exelixis BioMarin Pharmaceutical Madrigal Pharmaceuticals Repligen Halozyme Therapeutics Exact Sciences (NASDAQ:EXAS) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership. Which has more volatility and risk, EXAS or BIIB? Exact Sciences has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500. Does the media prefer EXAS or BIIB? In the previous week, Biogen had 28 more articles in the media than Exact Sciences. MarketBeat recorded 44 mentions for Biogen and 16 mentions for Exact Sciences. Biogen's average media sentiment score of 1.04 beat Exact Sciences' score of 0.94 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exact Sciences 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 21 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Is EXAS or BIIB more profitable? Biogen has a net margin of 15.31% compared to Exact Sciences' net margin of -34.19%. Biogen's return on equity of 13.85% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Exact Sciences-34.19% -1.75% -0.76% Biogen 15.31%13.85%8.32% Do insiders and institutionals have more ownership in EXAS or BIIB? 88.8% of Exact Sciences shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 1.2% of Exact Sciences shares are held by insiders. Comparatively, 0.2% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, EXAS or BIIB? Biogen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExact Sciences$2.94B4.16-$1.03B-$5.43-11.90Biogen$10.00B2.20$1.63B$10.4614.33 Do analysts prefer EXAS or BIIB? Exact Sciences currently has a consensus price target of $69.90, suggesting a potential upside of 8.14%. Biogen has a consensus price target of $180.69, suggesting a potential upside of 20.55%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Exact Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exact Sciences 1 Sell rating(s) 2 Hold rating(s) 19 Buy rating(s) 2 Strong Buy rating(s) 2.92Biogen 0 Sell rating(s) 20 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.35 SummaryBiogen beats Exact Sciences on 10 of the 17 factors compared between the two stocks. Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.28B$3.43B$6.24B$10.69BDividend YieldN/A2.27%5.72%4.82%P/E Ratio-11.9027.2231.2830.77Price / Sales4.16462.81563.45174.94Price / Cash11.5246.1437.0861.44Price / Book4.9810.4012.056.61Net Income-$1.03B-$52.83M$3.33B$277.10M7 Day Performance5.57%2.10%1.93%2.56%1 Month Performance20.42%12.33%7.77%3.77%1 Year Performance-6.47%14.14%56.40%33.01% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.4353 of 5 stars$64.64-0.3%$69.90+8.1%-8.0%$12.28B$2.94B-11.907,000Analyst ForecastBIIBBiogen4.7276 of 5 stars$146.63+2.5%$180.69+23.2%-18.5%$20.97B$9.68B14.027,605Trending NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionUTHRUnited Therapeutics4.846 of 5 stars$432.69-0.1%$457.21+5.7%+19.5%$19.55B$2.88B16.891,305Positive NewsUpcoming EarningsAnalyst ForecastInsider TradeINCYIncyte4.4895 of 5 stars$86.17-1.6%$84.79-1.6%+39.9%$17.10B$4.24B19.582,617Upcoming EarningsAnalyst ForecastNBIXNeurocrine Biosciences4.3215 of 5 stars$141.33+0.9%$163.72+15.8%+24.7%$13.89B$2.36B41.811,800Upcoming EarningsAnalyst ForecastIONSIonis Pharmaceuticals3.4728 of 5 stars$73.55+0.6%$78.50+6.7%+82.8%$11.65B$705M-39.971,069Analyst ForecastEXELExelixis4.7584 of 5 stars$34.54-12.0%$44.42+28.6%+37.7%$10.57B$2.17B16.611,147Analyst UpgradeAnalyst RevisionGap DownHigh Trading VolumeBMRNBioMarin Pharmaceutical4.9836 of 5 stars$53.07-0.4%$93.26+75.7%-22.6%$10.23B$2.85B15.753,040News CoveragePositive NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionMDGLMadrigal Pharmaceuticals4.824 of 5 stars$439.97+0.2%$532.70+21.1%+107.6%$9.75B$180.13M-34.2490Positive NewsAnalyst ForecastRGENRepligen4.1864 of 5 stars$154.54+1.3%$169.62+9.8%+23.0%$8.58B$634.44M-618.141,778Analyst ForecastHALOHalozyme Therapeutics4.8524 of 5 stars$66.47-0.8%$72.89+9.7%+34.2%$7.84B$1.02B15.21390Analyst Forecast Related Companies and Tools Related Companies Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Ionis Pharmaceuticals Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Madrigal Pharmaceuticals Alternatives Repligen Alternatives Halozyme Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXAS) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
